亲爱的研友该休息了!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!身体可是革命的本钱,早点休息,好梦!

Combination of hepatic artery infusion chemotherapy and PD1 immune checkpoint inhibitor improve survival in patients with KRAS-mutated unresectable colorectal liver metastases: A propensity score matching study

克拉斯 医学 危险系数 内科学 倾向得分匹配 结直肠癌 奥沙利铂 胃肠病学 化疗 混淆 比例危险模型 肿瘤科 癌症 置信区间
作者
Hao Hu,Fulei Gao,Maohuan Lin,Rong Liu,Jiachang Chi,Jinhe Guo
出处
期刊:Journal of Cancer Research and Therapeutics [BioMed Central]
卷期号:21 (4): 818-826 被引量:1
标识
DOI:10.4103/jcrt.jcrt_1869_23
摘要

OBJECTIVE: This study examined the effect of hepatic arterial infusion chemotherapy (HAIC) plus programmed death 1 inhibitors (HAICPs) in patients with unresected colorectal cancer liver metastases (UCRLM) with and without KRAS mutations. MATERIALS AND METHODS: We retrospectively collected data from patients with UCRLM, who received HAIC with HAICP or HAIC alone (oxaliplatin plus fluorouracil), including information on KRAS status (mutated, MUT; wild-type, WT) from a multicenter institutional database. Propensity score matching (PSM) was performed. The associations of KRAS status, treatment, and clinicopathological features with outcomes were determined. Confounding factors were adjusted using the Cox proportional hazard model. RESULTS: A total of 668 patients (414 KRAS-WT, 254 MUT) were followed for a median of 4.6 years post-HAIC. Fifty-five percent received HAICP. Before PSM, patients in the HAICP group exhibited a significantly higher CEA level (P = 0.014), more tumor nodules (P = 0.012), lower clinical risk score (P = 0.009), and fewer extrahepatic metastases (P = 0.017). After PSM analysis, 260 pairs of patients were established. The 5-year progression-free survival (PFS) for patients treated with HAICP versus HAIC was 36% and 31%, respectively (hazard ratio, 0.64; 95% CI, 0.48-0.85; P = 0.008). The 5-year overall survival (OS) for patients treated with HAICP versus HAIC was 72% and 64%, respectively (hazard ratio, 0.44; 95% CI, 0.32-0.63; P < 0.001). In KRAS-WT tumors, the 5-year survival was 79% and 61% for patients treated with HAICP versus HAIC (P < 0.001), respectively. In KRAS-MUT tumors, the 5-year survival was 68% and 52% for patients treated with HAICP versus HAIC (P < 0.001), respectively. CONCLUSION: The combined application of HAICP is an effective regimen for treating patients with UCRLM. HAICP shows superior survival independent of KRAS mutation. In addition, HAICP ameliorates the poor survival observed among KRAS-MUT UCRLM cases.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
Techmarine完成签到,获得积分10
刚刚
4秒前
7秒前
Cpp完成签到 ,获得积分10
8秒前
8秒前
如意行天完成签到 ,获得积分10
8秒前
10秒前
小林太郎发布了新的文献求助100
12秒前
Lucas的应助被张世琪采纳,获得10
13秒前
红宝石设计局完成签到,获得积分10
13秒前
14秒前
15735802374完成签到 ,获得积分10
15秒前
卓涛完成签到,获得积分10
19秒前
哇咔咔发布了新的文献求助10
21秒前
22秒前
chifan完成签到 ,获得积分10
23秒前
诚心铅笔完成签到,获得积分10
24秒前
过眼云烟完成签到,获得积分10
25秒前
25秒前
张世琪发布了新的文献求助10
26秒前
28秒前
28秒前
D4C发布了新的文献求助20
30秒前
33秒前
高高的网络完成签到,获得积分10
34秒前
哇咔咔完成签到,获得积分10
34秒前
null的应助被科研通管家采纳,获得10
35秒前
null的应助被科研通管家采纳,获得10
35秒前
嘻嘻哈哈的应助被科研通管家采纳,获得10
36秒前
嘻嘻哈哈的应助被科研通管家采纳,获得10
36秒前
华仔的应助被科研通管家采纳,获得10
36秒前
天天快乐的应助被科研通管家采纳,获得10
36秒前
36秒前
42秒前
yinh完成签到 ,获得积分10
42秒前
乐观小蕊完成签到 ,获得积分10
42秒前
369ninja发布了新的文献求助10
42秒前
Cupid完成签到,获得积分10
48秒前
洪亮发布了新的文献求助30
48秒前
49秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
Grapes 1000
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8179680
求助须知:如何正确求助?哪些是违规求助? 9569938
关于积分的说明 21807764
捐赠科研通 7775242
什么是DOI,文献DOI怎么找? 3433072
关于科研通互助平台的介绍 2557044
邀请新用户注册赠送积分活动 2478783